N/A
N=21
Effectiveness of Respiratory Physiotherapy in Children With Neuromuscular Disease
Neuromuscular Diseases
Bottom Line
View on ClinicalTrials.gov: NCT02743702 ↗Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Jul 2016
Primary outcome: Primary: Change From Baseline Vital Capacity at One Year. — 33.33; -7.41 percentage of Change of vital capacity — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- RESPIRATORY PHYSIOTHERAPY (Other); USUAL THERAPIES (Other)
- Age
- Pediatric, Adult · 3+ yrs
- Sex
- All
- Sponsor
- University of Seville
- Primary completion
- Jun 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline Vital Capacity at One Year. |
33.33; -7.41 | <0.001 sig |
Summary
The main objective of this study is to determine whether the Respiratory Physiotherapy allows improvement or maintenance of respiratory function in children with Neuromuscular Diseases, against respiratory deterioration that occurs in the group of subjects who did not receive this treatment. And to determine whether decreasing the number of respiratory infections and secondly the need for antibiotics and the number of emergency room visits and hospital admissions related to these.
Eligibility Criteria
Inclusion Criteria
- Being diagnosed with a Disease of the Neuromuscular junction, according to International Classification of Diseases 10.
- Be aged between 3 and 18 years.
Exclusion Criteria
- Being unable to perform spirometry, for physical or psychological difficulties.
- Be involved in another program Respiratory Physiotherapy.
- Present some kind of associated pathology (such as broken ribs, state epilepticus ...) in which it is contraindicated any maneuvers of the respiratory therapy protocol designed.
- If researchers are informed of the existence of a serious illness of the father / mother / tutor that preclude to carrying out the program of respiratory Physiotherapy at home.
Data sourced from ClinicalTrials.gov (NCT02743702). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.